Abstract Janus kinase 2 (JAK2) hyperactivation by JAK2V617F mutation leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 could serve as a promising therapeutic strategy for MPNs. Here, we report that Flonoltinib Maleate (FM), a selective JAK2/FLT3 inhibitor, shows high selectivity for JAK2 over the JAK family. Surface plasmon resonance assays verified that FM had a stronger affinity […]

MPN Specialist Explains PTG-300 and Clinical Trial for PV Patients
by David Wallace Hepcidin Mimetic PTG-300 Promising Treatment for PV How does PTG-300 work to reduce or eliminate the need for phlebotomy in PV? How does iron deficiency play a role in polycythemia vera? What are the goals of this treatment? Leading MPN expert, Dr. Srdan Verstovsek, from MD Anderson Cancer Center, interviews with David […]
Protagonist Therapeutics early Phase 2 results for Polycythemia Vera Treatment Encouraging
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis Results to be presented today by Ronald Hoffman, M.D., Director of the Myeloproliferative Diseases Program at The Icahn […]
Constellation Pharmaceuticals Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) – Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an update on progress in the MANIFEST Phase 2 clinical trial of CPI-0610 in myelofibrosis (MF). The Company also reviewed its 2018 accomplishments and announced its data […]
Incyte conducts Phase 2 Clinical Trials for Myelofibrosis and Essential Thrombocythemia
Myelofibrosis A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis Talk to your doctor if you are interested in participating […]
- 1
- 2
- 3
- 4
- Next Page »